Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with the gastritis and healthy patients, serum miR-25 level was significantly up-regulated in patients with GC.
|
30909187 |
2019 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SLC34A2 regulates miR-25-Gsk3β signaling pathway to affect tumor progression in gastric cancer stem cell-like cells.
|
29178392 |
2018 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting miR-25 may be a promising therapeutic approach to treat patients with cisplatin-resistant GC.
|
29113252 |
2017 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of miR-25 was found capable of elevating the expression of COL1A2 and inhibiting E-cadherin expression, revealing the diffuse type gastric cancer suppressive role conferred by miR-25. miR-25 was also found to suppress p53, and activate c-Src revealing its intestinal type gastric cancer associated oncogenic functions.
|
28059478 |
2017 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, rs41274221 in miR-25 was a subgroup which may protect the patients from further growth and metastasis of gastric cancer and might serve as a novel biomarker for the disease.
|
26572149 |
2016 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In our previous study, a panel of five circulating miRNAs (miR-16, miR-25, miR-92a, miR-451 and miR-486-5p) can be used as a potential biomarker for detecting of early-stage gastric carcinoma (GC).
|
27605261 |
2016 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BACKGROUND Gastric carcinoma is the second leading cause of cancer death. microRNAs play vital roles in regulating expression of related oncogenes. microRNA-25 (miR-25) has been found to be up-regulated in gastric carcinoma.
|
27120728 |
2016 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Findings of this study demonstrated that total miR-107 or miR-25 expression might be overexpressed in gastric cancer patients and they can simultaneously and synchronically regulate LATS2 expression, thereby affecting gastric cancer cell growth and invasion.
|
25824045 |
2015 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, miR-25 promotes GC progression by directly downregulating FBXW7 expression and may be employed as a novel prognostic marker and therapeutic target of GC.
|
25944166 |
2015 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, miR-25 promotes GC progression by directly downregulating TOB1 expression, and may be a noninvasive biomarker for the prognosis of GC patients.
|
25043310 |
2015 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulation of the expression of these miRNAs in GC also supports our findings, altogether suggesting for the fist time that genetic variation in MIR29, MIR25, MIR93 and MIR106b may have a critical role in genetic susceptibility to GC and could contribute to the molecular mechanisms of gastric carcinogenesis.
|
24643999 |
2014 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we confirmed that miR-25 was significantly increased in human GC tissues and cell lines.
|
24078004 |
2014 |